Have a personal or library account? Click to login
Adipokine levels and T786C polymorphism of eNOS gene promoter correlation in patients with arterial hypertension Cover

Adipokine levels and T786C polymorphism of eNOS gene promoter correlation in patients with arterial hypertension

Open Access
|Mar 2025

References

  1. Colombo MG, Paradossi U, Andreassi MG, Botto N, Manfredi S, Masetti S, Biagini A, Clerico A. Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 49, 389–395, 2003.
  2. Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, Kangawa K. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev 57, 541–546, 2005.
  3. Hnizdyukh R, Pidruchna S, Shmanko V, Lykhatskyi P, Palytsia L, Zavarynska I, Tkachuk N, Tokarskyy O. The lipid profile depends on the endothelial NO synthase gene promoter T786C-polymorphism in patients with arterial hypertension. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 31, 242–247, 2024.
  4. Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol 8, 1031–1063, 2018.
  5. Gomma AH, Elrayess MA, Knight CJ. The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 23, 1955–1962, 2002.
  6. Galletti F, D’Elia L, De Palma D, Russo O, Barba G, Siani A, Miller MA, Cappuccio FP, Rossi G, Zampa G, Strazzullo P. Hyperleptinemia is associated with hypertension, systemic inflammation and insulin resistance in over-weight but not in normal weight men. Nutr Metab Cardiovasc Dis 22, 300–306, 2012.
  7. Jiang Y, Lu L, Hu Y, Li Q, An C, Yu X, Shu L, Chen A, Niu C, Zhou L, Yang Z. Resistin induces hypertension and insulin resistance in mice via a TLR4-dependent pathway. Sci Rep 6, 22193, 2016.
  8. Khera AV, Qamar A, Murphy SA, Cannon CP, Sabatine MS, Rader DJ. On-statin resistin, leptin, and risk of recurrent coronary events after hospitalization for an acute coronary syndrome (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 study). Am J Cardiol 116, 694–698, 2015.
  9. Korda M, Yavorska S, Yaroshenko T, Ostrivka O, Pidruchna S, Suslova N, Kuzmak I. The role of leptin in obesity induced nitrooxidative stress and endothelial dysfunction-nanomedical approach. Pharmacia 23, 215–220, 2010.
  10. Krynytska I, Kucher S, Tokarskyy O, Koval M, Marushchak, M. The association of angiotensin-converting enzyme gene insertion/deletion polymorphism with bronchial asthma. Pol Merkur Lek 49, 442–444, 2021.
  11. Niu W, Qi Y. An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with hypertension. PLoS One 6(9), e24266, 2011.
  12. Marushchak M, Krynytska I, Tokarskyy O, Koval M, Demianchuk M. Genetic polymorphism of the angiotensin-converting enzyme in bronchial asthma. Bangladesh J Med Sci 21, 492, 2022.
  13. Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, Federspil G, Vettor R. Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 10, 1095–103, 2002.
  14. Park HK, Ahima RS. Resistin in rodents and humans. Diabetes Metab J 37, 404–414, 2013.
  15. Pidruchna S, Shmanko V, Hnizdyukh R, Sverstiuk A, Lykhatskyy P, Kuzmak I, Yaroshenko T, Bandas I, Vasylyshyn N, Ostrivka O, Mudra M, Palytsia L, Letnyak N, Tokarskyy O. Statistically verified methods for determining predictors of development of arterial hypertension depending on endothelial nitric oxide synthase T786C gene promoter polymorphism using lipid profile indicators. Endocr Regul 58, 138–143, 2024a.
  16. Pidruchna S, Shmanko V, Zakharchuk U, Tokarskyy O, Hnizdyukh R, Lynkhatskyi P, Kuzmak I, Yaroshenko T, Bandas I, Vasylyshyn N, Ostrivka O, Mudra A, Palytsya L, Letniak N, Pohorielova O. Changes in adipokine indicators depending on A1166C polymorphism of the angiotensin II type 1 receptor gene as a predictor of the arterial hypertension. Endocr Regul 58, 153–157, 2024b.
  17. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52, 2546–2553, 2003.
  18. Rojas E, Rodriguez-Molina D, Bolli P, Israili ZH, Faria J, Fidilio E, Bermudez V, Velasco M. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep 16, 463, 2014.
  19. Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial nitric oxide synthase (eNOS) and the cardiovascular system: in physiology and in disease states. Am J Biomed Sci Res 15, 153–177, 2022.
  20. Tritos NA, Kokkotou EG. The physiology and potential clinical applications of ghrelin, a novel peptide hormone. Mayo Clin Proc 81, 653–660, 2006.
  21. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 409, 307–312, 2001.
  22. Yaremchuk OZ, Posokhova KA, Kuzmak ІP, Kulitska MI, Klishch IМ, Korda MM. Indexes of nitric oxide system in experimental antiphospholipid syndrome. Ukr Biochem J 92, 75–83, 2020.
DOI: https://doi.org/10.2478/enr-2025-0003 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668
Language: English
Page range: 17 - 23
Published on: Mar 12, 2025
Published by: Slovak Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year

© 2025 Svitlana Pidruchna, Uliana Zakharchuk, Olga Svan, Bohdan Zablotskyi, Oleksandr Tokarskyy, published by Slovak Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.